Nautilus Biotechnology, Inc. — Director's Dealing 2021

Dec 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-11-30

Reporting Person: Posard Matthew L. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-30	Common Stock	P	20000	$4.57	Acquired	20000	Direct
2021-12-01	Common Stock	P	10000	$4.50	Acquired	30000	Direct
2021-12-01	Common Stock	P	10000	$4.4612	Acquired	40000	Direct
2021-12-01	Common Stock	P	10000	$4.4493	Acquired	50000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	100000	Indirect

Footnotes

F1: Shares held by the Matthew and Elizabeth Posard Trust. The reporting person is the Trustee of the Matthew and Elizabeth Posard Trust.